UA86617C2 - 2-(1-AZA-BICYCLO[2.2.2]OCT-3-YL)-2,3-DIHYDROISOINDOL-l-ONE/5,6-DIHYDRO-FURO[2,3-c]PYRROL-4-ONE DERIVATIVES AS LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR - Google Patents
2-(1-AZA-BICYCLO[2.2.2]OCT-3-YL)-2,3-DIHYDROISOINDOL-l-ONE/5,6-DIHYDRO-FURO[2,3-c]PYRROL-4-ONE DERIVATIVES AS LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORInfo
- Publication number
- UA86617C2 UA86617C2 UAA200610315A UAA200610315A UA86617C2 UA 86617 C2 UA86617 C2 UA 86617C2 UA A200610315 A UAA200610315 A UA A200610315A UA A200610315 A UAA200610315 A UA A200610315A UA 86617 C2 UA86617 C2 UA 86617C2
- Authority
- UA
- Ukraine
- Prior art keywords
- nicotinic acetylcholine
- dihydroisoindol
- furo
- pyrrol
- aza
- Prior art date
Links
- PJGZWNLFHXMTSZ-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yl)-3h-isoindol-1-one Chemical compound C1N(CC2)CCC2C1N1C(=O)C2=CC=CC=C2C1 PJGZWNLFHXMTSZ-UHFFFAOYSA-N 0.000 title 1
- YGCWQYOIPFWXLF-UHFFFAOYSA-N 5,6-dihydrofuro[2,3-c]pyrrol-4-one Chemical class O1C=CC2=C1CNC2=O YGCWQYOIPFWXLF-UHFFFAOYSA-N 0.000 title 1
- 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 title 1
- 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 abstract 1
- 229960004373 acetylcholine Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0400970A SE0400970D0 (sv) | 2004-04-14 | 2004-04-14 | Nicotinic acetylcholine receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA86617C2 true UA86617C2 (en) | 2009-05-12 |
Family
ID=32294312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200610315A UA86617C2 (en) | 2004-04-14 | 2005-06-04 | 2-(1-AZA-BICYCLO[2.2.2]OCT-3-YL)-2,3-DIHYDROISOINDOL-l-ONE/5,6-DIHYDRO-FURO[2,3-c]PYRROL-4-ONE DERIVATIVES AS LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7566727B2 (enExample) |
| EP (1) | EP1737854A1 (enExample) |
| JP (1) | JP2007532637A (enExample) |
| CN (1) | CN1968951A (enExample) |
| AU (1) | AU2005233492B2 (enExample) |
| BR (1) | BRPI0509777A (enExample) |
| CA (1) | CA2563010A1 (enExample) |
| IL (1) | IL178241A0 (enExample) |
| NO (1) | NO20065199L (enExample) |
| RU (2) | RU2372350C2 (enExample) |
| SE (1) | SE0400970D0 (enExample) |
| UA (1) | UA86617C2 (enExample) |
| WO (1) | WO2005100351A1 (enExample) |
| ZA (1) | ZA200608412B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7807706B2 (en) | 2005-08-12 | 2010-10-05 | Astrazeneca Ab | Metabotropic glutamate-receptor-potentiating isoindolones |
| TW200804281A (en) * | 2006-02-16 | 2008-01-16 | Astrazeneca Ab | New metabotropic glutamate receptor-potentiating isoindolones |
| TWI417100B (zh) | 2007-06-07 | 2013-12-01 | Astrazeneca Ab | 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途 |
| WO2009042907A1 (en) * | 2007-09-27 | 2009-04-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| US7790760B2 (en) | 2008-06-06 | 2010-09-07 | Astrazeneca Ab | Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286 |
| US8669259B2 (en) | 2009-08-26 | 2014-03-11 | Merck Sharp & Dohme Corp. | Heterocyclic amide compounds as protein kinase inhibitors |
| KR101758046B1 (ko) * | 2009-12-22 | 2017-07-14 | 버텍스 파마슈티칼스 인코포레이티드 | 포스파티딜이노시톨 3-키나제의 이소인돌리논 억제제 |
| KR20120125618A (ko) | 2009-12-31 | 2012-11-16 | 피라말 헬쓰케어 리미티드 | 디아실글리세롤 아실 전이효소의 억제제 |
| JO3383B1 (ar) * | 2013-03-14 | 2019-03-13 | Lilly Co Eli | مثبطات cdc7 |
| US10329289B2 (en) | 2015-12-23 | 2019-06-25 | Merck Sharp & Dohme Corp. | 6,7-dihydro-5H-pyrrolo[3,4-B]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor |
| WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
| KR20190093205A (ko) | 2016-12-21 | 2019-08-08 | 바이오테릭스, 인코포레이티드 | 단백질 표적화에 사용하기 위한 티에노피롤 유도체, 조성물, 방법 및 이의 용도 |
| WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
| WO2018210229A1 (zh) * | 2017-05-18 | 2018-11-22 | 南京明德新药研发股份有限公司 | α-7尼古丁乙酰胆碱受体激动剂及应用 |
| CN107188900B (zh) * | 2017-05-27 | 2019-09-06 | 北京师范大学 | α7烟碱型乙酰胆碱受体的配体化合物及其应用 |
| WO2018226545A1 (en) * | 2017-06-09 | 2018-12-13 | Merck Sharp & Dohme Corp. | Azabicyclo[4.1.0]heptane allosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2019000238A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000236A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000237A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| NL2021185B1 (en) | 2018-06-26 | 2020-01-06 | Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis | Combination Therapy and Use Thereof for Treating Cancer |
| EP4251149A4 (en) * | 2020-11-24 | 2024-10-30 | Merck Sharp & Dohme LLC | MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5491148A (en) * | 1991-04-26 | 1996-02-13 | Syntex (U.S.A.) Inc. | Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists |
| SE9201478D0 (sv) * | 1992-05-11 | 1992-05-11 | Kabi Pharmacia Ab | Heteroaromatic quinuclidinenes, their use and preparation |
| NO2005012I1 (no) * | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
| IT1303123B1 (it) * | 1998-10-13 | 2000-10-30 | Rotta Research Lab | Derivati basici di benz(e)isoindol-1-oni e pirrolo(3,4-c)chinolin-1-oni ad attivita' 5ht3 antagonista, loro preparazione ed |
| DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
| ATE385497T1 (de) * | 2000-12-01 | 2008-02-15 | Neurosearch As | 3-substituierte quinuclidin-derivate und deren verwendung als nikotinischen agonisten |
| DE10118551A1 (de) * | 2001-04-14 | 2002-10-17 | Merck Patent Gmbh | Nikotinische Acetylcholinrezeptor Liganden |
| NZ529880A (en) * | 2001-07-06 | 2005-09-30 | Neurosearch As | Novel compounds, their preparation and use |
| EP1532144B1 (en) * | 2002-08-14 | 2008-01-23 | Neurosearch A/S | quinuclidine derivatives and their use |
-
2004
- 2004-04-14 SE SE0400970A patent/SE0400970D0/xx unknown
-
2005
- 2005-04-06 CN CNA2005800194932A patent/CN1968951A/zh active Pending
- 2005-04-06 EP EP05722314A patent/EP1737854A1/en not_active Withdrawn
- 2005-04-06 JP JP2007508300A patent/JP2007532637A/ja active Pending
- 2005-04-06 WO PCT/SE2005/000500 patent/WO2005100351A1/en not_active Ceased
- 2005-04-06 CA CA002563010A patent/CA2563010A1/en not_active Abandoned
- 2005-04-06 AU AU2005233492A patent/AU2005233492B2/en not_active Expired - Fee Related
- 2005-04-06 RU RU2006135481/04A patent/RU2372350C2/ru not_active IP Right Cessation
- 2005-04-06 US US10/599,839 patent/US7566727B2/en not_active Expired - Fee Related
- 2005-04-06 BR BRPI0509777-0A patent/BRPI0509777A/pt not_active IP Right Cessation
- 2005-06-04 UA UAA200610315A patent/UA86617C2/ru unknown
-
2006
- 2006-09-21 IL IL178241A patent/IL178241A0/en unknown
- 2006-10-09 ZA ZA200608412A patent/ZA200608412B/xx unknown
- 2006-11-13 NO NO20065199A patent/NO20065199L/no not_active Application Discontinuation
-
2009
- 2009-07-10 RU RU2009126341/04A patent/RU2009126341A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2006135481A (ru) | 2008-05-20 |
| US7566727B2 (en) | 2009-07-28 |
| IL178241A0 (en) | 2006-12-31 |
| SE0400970D0 (sv) | 2004-04-14 |
| NO20065199L (no) | 2006-11-13 |
| WO2005100351A1 (en) | 2005-10-27 |
| RU2372350C2 (ru) | 2009-11-10 |
| US20070213342A1 (en) | 2007-09-13 |
| CN1968951A (zh) | 2007-05-23 |
| BRPI0509777A (pt) | 2007-10-23 |
| AU2005233492A1 (en) | 2005-10-27 |
| CA2563010A1 (en) | 2005-10-27 |
| RU2009126341A (ru) | 2011-01-20 |
| AU2005233492B2 (en) | 2009-06-11 |
| ZA200608412B (en) | 2008-09-25 |
| JP2007532637A (ja) | 2007-11-15 |
| EP1737854A1 (en) | 2007-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA86617C2 (en) | 2-(1-AZA-BICYCLO[2.2.2]OCT-3-YL)-2,3-DIHYDROISOINDOL-l-ONE/5,6-DIHYDRO-FURO[2,3-c]PYRROL-4-ONE DERIVATIVES AS LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR | |
| UA86614C2 (ru) | Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата | |
| BRPI0614168A2 (pt) | Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto | |
| WO2007091948A3 (en) | Novel spiro [imidazolidine-4, 3´-indole] 2, 2´,5´(1h) triones for treatment of conditions associated with vanilloid receptor 1 | |
| AP1822A (en) | Substituted pyridinones as modulators of P38 MAP kinase. | |
| MX340965B (es) | Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular. | |
| TW200517109A (en) | Substituted pyridinones | |
| MXPA06000231A (es) | Derivados espiro '1-azabiciclo'2.2.2!octan-3,5'-oxazolidin-2'-ona! con afinidad a la alfa7 del receptor nicotinico para acetilcolina. | |
| WO2004087677A3 (en) | Pyrimidin-4-one derivatives and their use as p38 kinase modulators | |
| WO2007040438A3 (en) | Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders | |
| BRPI0713923B8 (pt) | compostos de ciclopentanos de pirimidila hidroxilados e metoxilados, composição farmacêutica compreendendo os referidos compostos, método de preparação de um composto, e uso dos mesmos | |
| MY155836A (en) | Thienopyridone derivatives as amp-activated protein kinase (ampk) activators | |
| ATE457988T1 (de) | A2a-adenosin-rezeptor-antagonisten | |
| BRPI0708490B8 (pt) | composto, composição farmacêutica, processo para preparar um composto da fórmula (i), e uso de um composto | |
| WO2008010238A3 (en) | Antidiabetic azabicyclo [3. 1. 0] hexan compounds | |
| BRPI0407253A (pt) | Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos | |
| MX2023010087A (es) | Derivados heterociclicos como inhibidores de cinasas jano. | |
| NO20070837L (no) | Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer. | |
| ATE446089T1 (de) | 2-benzoyl-imidazopyridin-derivate, herstellungsverfahren und ihre verwendung für therapeutika | |
| BRPI0315958B8 (pt) | composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto | |
| BR0211171A (pt) | Compostos quìmicos | |
| MX2023010083A (es) | Derivados heterociclicos como inhibidores de cinasas jano. | |
| BR0317433A (pt) | Derivados bicìclicos para o tratamento do crescimento celular anormal | |
| PL1869038T3 (pl) | Podstawione pochodne 5,6,7,8-tetrahydro-imidazo[1,2-a]pirydyn-2-yloaminy i ich zastosowanie do wytwarzania środków leczniczych | |
| WO2006055434A3 (en) | Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease |